This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
19-21 March 2024
Westin Miyako KyotoKyoto, Japan
REGISTER NOW
Menu
Sign Up
Key Sessions
Andrew Bellinger, MD, PhD
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease
Verve Therapeutics
Brian Cafferty, PhD
From Circles to Conjugates: Rethinking the Architecture of guide RNA
Beam Therapeutics
keyboard_arrow_right

Day 2

keyboard_arrow_leftSearch & Filter
search

Day 2

search
8:00am - 8:40am
Registration and Coffee
Plenary Session
Showing 1 of 1 Streams
8:40am - 8:45am
Chairperson’s Remarks
8:45am - 9:15am
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease
  • Andrew Bellinger, MD, PhD - Chief Scientific Officer, Verve Therapeutics
9:15am - 9:45am
From Circles to Conjugates: Rethinking the Architecture of guide RNA
  • Brian Cafferty, PhD - Director, Beam Therapeutics
9:45am - 10:15am
Improving Oligonucleotide Pharmacology Across Tissues and Modalities through Base, Sugar, and Backbone Modifications
  • Michael Byrne, Ph.D. - Vice President, In Vivo and CNS Biology, Wave Life Sciences
10:15am - 10:55am
Networking Refreshment Break with Poster and Exhibit Viewing
Concurrent Conference Tracks
Showing 2 of 2 Streams
10:55am - 11:00am
Chairperson’s Remarks
11:00am - 11:30am
Bivalent Nucleic Acid Recognition and Its Applications in Targeting RNA Triplet-Repeats
  • Danith Ly, Ph.D. - Professor of Chemistry, Carnegie Mellon University
11:30am - 12:00pm
Amide-Modified Oligonucleotides for Chemical Control of Functional RNAs
  • Eriks Rozners, Ph.D. - Professor and Chair of Chemistry Department, Binghamton University
12:00pm - 12:30pm
Chemical Approaches to Enhance siRNA Selectivity
  • Mehran Nikan, Ph.D. - Research Fellow, Ionis Pharmaceuticals Inc
10:55am - 11:00am
Chairperson’s Remarks
11:00am - 11:30am
Synthesizing Long Guide RNAs for In Vivo Prime Editing
  • Rowshon Alam, Ph.D. - Senior Director, Head of Process Chemistry, Prime Medicine
11:30am - 12:00pm
Addressing the Regulatory Expectations for Guide RNA Quality While Providing Manufacturing Capacity
  • Blake Unterreiner - Associate Vice President, Business Development & Customer Relations, Agilent Technologies
12:00pm - 12:30pm
Delivery of Genetic Medicine with Hydrophilic Nanoparticles
  • Kunwoo Lee, PhD - Chief Executive Officer, GenEdit
12:30pm - 1:30pm
Networking Luncheon with Poster and Exhibit Viewing
Showing 2 of 2 Streams
1:30pm - 1:35pm
Chairperson’s Remarks
1:35pm - 2:00pm
Synthetic Strategy for Ligand Conjugated Oligonucleotides via Diamine Modified Stable Phosphoroamidite
  • Mitsuaki Sekiguchi, Ph.D. - Principal Scientist, Biopharmaceutical Research Di, Shionogi & Co., Ltd.
2:00pm - 2:25pm
Impurity Analysis of Phosphoramidites for Manufacturing Oligonucleotide Therapeutics
  • Gary Held - Staff Scientist, Analytical Development, Thermo Fisher Scientific
2:25pm - 2:50pm
Overcoming Oligonucleotide Manufacturing Challenges
  • Loic Cornelissen, PhD - Sales Manager, PolyPeptide Group
2:50pm - 3:15pm
Going Large-scale with Manufacturing of Oligonucleotides
  • Daniel Samson, PhD - Vice President, Head Oligonucleotides, Bachem AG
1:40pm - 1:45pm
Chairperson’s Remarks
1:45pm - 2:15pm
De Novo Discovery of Natural Product-like Thiopeptides with Designed Biological Activities
  • Alexander Vinogradov, Ph.D. - Project Assistant Professor, The University of Tokyo
2:15pm - 2:45pm
Discovery of Macrocycles for Delivery of RNA and Targeted Radiopharmaceuticals
  • Ratmir Derda, PhD - Founder and CSO, 48Hour Discovery and Associate Professor, Department of Chemistry, University of Alberta
2:45pm - 3:15pm
Macrocyclic Peptide Drug Development by Combining the Strengths of all Small Fragments, mRNA Display and AI Technologies
  • Hwanho Choi, M.D., Ph.D. - CEO and Founder, Quantum Intelligence Corporation
3:15pm - 3:45pm
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
3:45pm - 4:15pm
Oligonucleotide CMC Topic TBA
  • Spenser Pruett - Scientist II, Process Development, Nitto Avecia
4:15pm - 4:45pm
Addressing Complex Oligonucleotide Therapeutics and Approach Towards Endotoxin Removal
  • Juergen Mueller, PhD - Vice President of Commercial Operations, LGC Axolabs
4:45pm - 5:15pm
New Ligation Approach: Technology for High Quality Manufacturing of Over 150 mer RNA
  • Masato Sanosaka, PhD - Group Leader of Research & Process Development, Ajinomoto Biopharma Services
3:45pm - 4:15pm
From Discovery to the Clinic: Development of a Novel Bioactive Peptide that Improves Mood and Cognition by Engaging the Gut-Brain Axis
  • Kousaku Ohinata, Ph.D. - Founder and Scientific Advisor, Viage Therapeutics
4:15pm - 4:45pm
A Purely Thermodynamic Anti-prionic Mode of Action for Protein-misfolding Diseases is Realized by All-D-peptides
  • Dieter Willbold, Ph.D. - Director and Full Professor, Forschungszentrum Jülich
4:45pm - 5:15pm
In Cellulo Library-derived Peptide-based Inhibitors of Alpha-synuclein Aggregation and Toxicity
  • Jody Mason, PhD - Professor of Biochemistry, University of Bath
5:15pm - 6:15pm
Networking Cocktail Reception with Poster and Exhibit Viewing

Please join your fellow attendees in the exhibit hall for an evening of networking while enjoying beverages and appetizers.

6:15pm - 6:20pm
Close of Day Two
Day 1
NextDay 3
Filter
Streams
Choose Day